Skip to main content
×
Home

“Much ado about nothing”: monoamine oxidase inhibitors, drug interactions, and dietary tyramine

  • Ken Gillman (a1)
  • View HTML
    • Send article to Kindle

      To send this article to your Kindle, first ensure no-reply@cambridge.org is added to your Approved Personal Document E-mail List under your Personal Document Settings on the Manage Your Content and Devices page of your Amazon account. Then enter the ‘name’ part of your Kindle email address below. Find out more about sending to your Kindle.

      Note you can select to send to either the @free.kindle.com or @kindle.com variations. ‘@free.kindle.com’ emails are free but can only be sent to your device when it is connected to wi-fi. ‘@kindle.com’ emails can be delivered even when you are not connected to wi-fi, but note that service fees apply.

      Find out more about the Kindle Personal Document Service.

      “Much ado about nothing”: monoamine oxidase inhibitors, drug interactions, and dietary tyramine
      Available formats
      ×
      Send article to Dropbox

      To send this article to your Dropbox account, please select one or more formats and confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your Dropbox account. Find out more about sending content to Dropbox.

      “Much ado about nothing”: monoamine oxidase inhibitors, drug interactions, and dietary tyramine
      Available formats
      ×
      Send article to Google Drive

      To send this article to your Google Drive account, please select one or more formats and confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your Google Drive account. Find out more about sending content to Google Drive.

      “Much ado about nothing”: monoamine oxidase inhibitors, drug interactions, and dietary tyramine
      Available formats
      ×
Abstract
Copyright
Corresponding author
*Address for correspondence: Ken Gillman, PsychoTropical Research, PO Box 86, Rural View, Queensland, 4740 Australia. (Email: kg@matilda.net.au)
References
Hide All
1. Paykel ES, White JL. A European study of views on the use of monoamine oxidase inhibitors. Br J Psychiatry. 1989; 155(Suppl 6): 917.
2. Balon R, Mufti R, Arfken CL. A survey of prescribing practices for monoamine oxidase inhibitors. Psychiatr Serv. 1999; 50(7): 945947.
3. Clary C, Mandos LA, Schweizer E. Results of a brief survey on the prescribing practices for monoamine oxidase inhibitor antidepressants. J Clin Psychiatry. 1990; 51(6): 226231.
4. Shulman KI, Fischer HD, Herrmann N, Huo CY, Anderson GM, Rochon PA. Current prescription patterns and safety profile of irreversible monoamine oxidase inhibitors: a population-based cohort study of older adults. J Clin Psychiatry. 2009; 70(12): 16811686.
5. Heijnen WT, De Fruyt J, Wierdsma AI, Sienaert P, Birkenhager TK. Efficacy of tranylcypromine in bipolar depression: a systematic review. J Clin Psychopharmacol. 2015; 35(6): 700705.
6. Grady MM, Stahl SM. Practical guide for prescribing MAOIs: debunking myths and removing barriers. CNS Spectr. 2012; 17(1): 210.
7. O’Brien V. The monoamine oxidase inhibitors: relics reconsidered. Psychiatric Annals. 2011; 41(3): 176183.
8. Gillman PK. Advances pertaining to the pharmacology and interactions of irreversible nonselective monoamine oxidase inhibitors. J Clin Psychopharmacol. 2011; 31(1): 6674.
9. Mallinger AG, Frank E, Thase ME, et al. Revisiting the effectiveness of standard antidepressants in bipolar disorder: are monoamine oxidase inhibitors superior? Psychopharmacol Bull. 2009; 42(2): 6474.
10. Fawcett J. Why aren’t MAOIs used more often? J Clin Psychiatry. 2009; 70(1): 139140.
11. Amsterdam JD, Shults J. MAOI efficacy and safety in advanced stage treatment-resistant depression—a retrospective study. J Affect Disord. 2005; 89(1–3): 183188.
12. Kennedy N, Paykel ES. Treatment and response in refractory depression: results from a specialist affective disorders service. J Affect Disord. 2004; 81(1): 4953.
13. Fiedorowicz JG, Swartz KL. The role of monoamine oxidase inhibitors in current psychiatric practice. J Psychiatr Pract. 2004; 10(4): 239248.
14. Nutt D, Glue P. Monoamine oxidase inhibitors: rehabilitation from recent research? Br J Psychiatry. 1989; 154(3): 287291.
15. Adli M, Pilhatsch M, Bauer M, et al. Safety of high-intensity treatment with the irreversible monoamine oxidase inhibitor tranylcypromine in patients with treatment-resistant depression. Pharmacopsychiatry. 2008; 41(6): 252257.
16. Parker G, Roy K, Wilhelm K, Mitchell P. Assessing the comparative effectiveness of antidepressant therapies: a prospective clinical practice study. J Clin Psychiatry. 2001; 62(2): 117125.
17. Parker G, Mitchell P, Wilhelm K, et al. Are the newer antidepressant drugs as effective as established physical treatments? Results from an Australasian clinical panel review. Aust N Z J Psychiatry. 1999; 33(6): 874881.
18. Gillman PK. CNS toxicity involving methylene blue: the exemplar for understanding and predicting drug interactions that precipitate serotonin toxicity. J Psychopharmacol. 2011; 25(3): 429436.
19. Wimbiscus M, Kostenko O, Malone D. MAO inhibitors: risks, benefits, and lore. Cleve Clin J Med. 2010; 77(12): 859882.
20. Gillman PK. A review of serotonin toxicity data: implications for the mechanisms of antidepressant drug action. Biol Psychiatry. 2006; 59(11): 10461051.
21. Gillman PK. Monoamine oxidase inhibitors, opioid analgesics and serotonin toxicity. Br J Anaesth. 2005; 95(4): 434441.
22. Gillman PK. Triptans, serotonin agonists, and serotonin syndrome (serotonin toxicity): a review. Headache. 2009; 50(2): 264272.
23. Isbister GK, Buckley NA, Whyte IM. Serotonin toxicity: a practical approach to diagnosis and treatment. Med J Aust. 2007; 187(6): 361365.
24. Shioda K, Nisijima K, Yoshino T, Kato S. Mirtazapine abolishes hyperthermia in an animal model of serotonin syndrome. Neurosci Lett. 2010; 482(3): 216219.
25. Gillman PK. A systematic review of the serotonergic effects of mirtazapine: implications for its dual action status. Hum Psychopharmacol. 2006; 21(2): 117125.
26. Otte W, Birkenhager TK, van den Broek WW. Fatal interaction between tranylcypromine and imipramine. Eur Psychiatry. 2003; 18(5): 264265.
27. Gillman PK. Serotonin syndrome: history and risk. Fundam Clin Pharmacol. 1998; 12(5): 482491.
28. Gillman PK. Tricyclic antidepressant pharmacology and therapeutic drug interactions updated. Br J Pharmacol. 2007; 151(6): 737748.
29. Sullivan EA, Shulman KI. Diet and monoamine oxidase inhibitors: a re-examination. Can J Psychiatry. 1984; 29(8): 707711.
30. Gillman PK. Monoamine oxidase inhibitors: A review concerning dietary tyramine and drug interactions. PsychoTropical Commentaries. 2016; 16(6): 197; http://www.psychotropical.com/images/Publications-pdfs/MAOI_diet_drug_interactions_2016.pdf. Accessed June 2017, 2016.
31. Bullock D, Irvine O. A chromatographic study of cheddar cheese ripening. Journal of Dairy Science. 1956; 39(9): 12291235.
32. Blackwell B, Marley E. Interactions of yeast extracts and their constituents with monoamine oxidase inhibitors. Br J Pharmacol. 1965; 26(1): 142161.
33. Tulman DB, Stawicki SP, Papadimos TJ, Murphy CV, Bergese SD. Advances in management of acute hypertension: a concise review. Discov Med. 2012; 13(72): 375383.
34. Marik PE, Rivera R. Hypertensive emergencies: an update. Curr Opin Crit Care. 2011; 17(6): 569580.
35. Flanigan JS, Vitberg D. Hypertensive emergency and severe hypertension: what to treat, who to treat, and how to treat. Med Clin North Am. 2006; 90(3): 439451.
36. Griesemer EC, Barsky J, Dragstedt CA, Wells JA, Zeller EA. Potentiating effect of iproniazid on the pharmacological action of sympathomimetic amines. Proc Soc Exp Biol Med. 1953; 84(3): 699701.
37. Corne S, Graham J. The effect of inhibition of amine oxidase in vivo on administered adrenaline, noradrenaline, tyramine and serotonin. J Physiol. 1957; 135(2): 339349.
Recommend this journal

Email your librarian or administrator to recommend adding this journal to your organisation's collection.

CNS Spectrums
  • ISSN: 1092-8529
  • EISSN: 2165-6509
  • URL: /core/journals/cns-spectrums
Please enter your name
Please enter a valid email address
Who would you like to send this to? *
×

Metrics

Full text views

Total number of HTML views: 238
Total number of PDF views: 453 *
Loading metrics...

Abstract views

Total abstract views: 674 *
Loading metrics...

* Views captured on Cambridge Core between 2nd February 2017 - 19th November 2017. This data will be updated every 24 hours.